Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial

SUMMARY: Abaloparatide increased ultradistal radius bone mineral density (BMD) in the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial. Over the subsequent 24 months in ACTIVExtend, ultradistal radius BMD gains were maintained with alendronate. Conversely, 1/3 radius BMD remained...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Osteoporos Int
Autori principali: Watts, N.B., Dore, R.K., Baim, S., Mitlak, B., Hattersley, G., Wang, Y., Rozental, T.D., LeBoff, M.S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer London 2020
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755646/
https://ncbi.nlm.nih.gov/pubmed/32935170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00198-020-05555-1
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi